Adaptimmune Therapeutics Files 2024 10-K
| Field | Detail |
|---|---|
| Company | Adaptimmune Therapeutics PLC |
| Form Type | 10-K |
| Filed Date | Mar 24, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, biotech
TL;DR
Adaptimmune dropped its 2024 10-K. Financials for FY24 are in.
AI Summary
Adaptimmune Therapeutics PLC filed its 2024 10-K on March 24, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, based in Abingdon, Oxfordshire, operates in the biological products sector. Key financial details such as retained earnings, additional paid-in capital, and accumulated other comprehensive income as of December 31, 2024, are included in the filing.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Adaptimmune's financial health and operational performance for the fiscal year 2024, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a biotechnology company, Adaptimmune Therapeutics PLC is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-03-24 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Adaptimmune Therapeutics PLC (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-24 (date) — Filing date
- Abingdon, Oxfordshire (location) — Company headquarters
FAQ
What is the primary business of Adaptimmune Therapeutics PLC?
Adaptimmune Therapeutics PLC is primarily involved in the biological products sector, specifically focusing on therapies.
When did Adaptimmune Therapeutics PLC file its 2024 10-K?
Adaptimmune Therapeutics PLC filed its 2024 10-K on March 24, 2025.
What is the fiscal year end for Adaptimmune Therapeutics PLC?
The fiscal year end for Adaptimmune Therapeutics PLC is December 31.
Where is Adaptimmune Therapeutics PLC headquartered?
Adaptimmune Therapeutics PLC is headquartered in Abingdon, Oxfordshire.
What are some of the key financial statement components reported as of December 31, 2024?
Key financial statement components reported as of December 31, 2024, include Retained Earnings, Additional Paid-In Capital, and Accumulated Other Comprehensive Income.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 24, 2025 regarding Adaptimmune Therapeutics PLC.